TACSTD2 and triple-negative breast carcinoma: The ADC sacituzumab govitecan (Trodelvy®) targets trophoblast cell-surface antigen-2 (TROP2) [6] and was FDA approved for patients with metastatic or locally advanced triple-negative breast cancer (TNBC) in 2021 [7].